Shibaki et al. revealed that higher levels of VEGF-A in serum were associated with shorter survival [25], although Tiako et al. showed that there was no significant association between VEGF-A levels in plasma and efficacy in patients with NSCLC [26]. Here, VEGFA is linked to non-small cell lung carcinoma.